Drug intelligence / Profile preview

Q Fever LPS Conjugate Vaccine

Development stage
Preclinical
Lead developer
Hilleman Laboratories
Modality
Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
01

Overview

The Q Fever LPS Conjugate Vaccine is a preclinical vaccine candidate being developed by Hilleman Laboratories for the prevention of Q Fever, a zoonotic infection caused by the bacterium *Coxiella burnetii*. The vaccine utilizes a conjugate platform where the lipopolysaccharide (LPS) of *C. burnetii* is chemically linked to a carrier protein. This design aims to overcome the limitations of traditional whole-cell vaccines, which can cause severe hypersensitivity reactions in individuals previously exposed to the pathogen. By conjugating the LPS antigen, the vaccine is intended to convert the T-cell independent carbohydrate antigen into a T-cell dependent one, thereby inducing a more robust and long-lasting immune response with an improved safety profile.

Other names
Coxiella burnetii LPS-conjugate vaccineQ fever lipopolysaccharide conjugate vaccine
02

Targets

Coxiella burnetii phase I lipopolysaccharide O-antigen epitopeCbLPS-I (Coxiella burnetii phase I lipopolysaccharide)

Beyond the preview

Go deeper on Q Fever LPS Conjugate Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q Fever LPS Conjugate Vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call